AU2020233286B2 - Systems, compositions, and methods for target entity detection - Google Patents

Systems, compositions, and methods for target entity detection Download PDF

Info

Publication number
AU2020233286B2
AU2020233286B2 AU2020233286A AU2020233286A AU2020233286B2 AU 2020233286 B2 AU2020233286 B2 AU 2020233286B2 AU 2020233286 A AU2020233286 A AU 2020233286A AU 2020233286 A AU2020233286 A AU 2020233286A AU 2020233286 B2 AU2020233286 B2 AU 2020233286B2
Authority
AU
Australia
Prior art keywords
target
cancer
detection
entity
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020233286A
Other languages
English (en)
Other versions
AU2020233286A1 (en
Inventor
Laura Teresa BORTOLIN
Daniel Parker SALEM
Joseph Charles SEDLAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mercy Bioanalytics Inc
Original Assignee
Mercy Bioanalytics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mercy Bioanalytics Inc filed Critical Mercy Bioanalytics Inc
Publication of AU2020233286A1 publication Critical patent/AU2020233286A1/en
Priority to AU2022241629A priority Critical patent/AU2022241629B2/en
Application granted granted Critical
Publication of AU2020233286B2 publication Critical patent/AU2020233286B2/en
Assigned to MERCY BIOANALYTICS, INC. reassignment MERCY BIOANALYTICS, INC. Amend patent request/document other than specification (104) Assignors: MERCY BIOANALYTICS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6862—Ligase chain reaction [LCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/501—Ligase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/101—Reactions characterised by their quantitative nature the purpose being quantitative analysis with an internal standard/control
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2020233286A 2019-03-01 2020-02-28 Systems, compositions, and methods for target entity detection Active AU2020233286B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022241629A AU2022241629B2 (en) 2019-03-01 2022-10-03 Systems, compositions, and methods for target entity detection

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962812878P 2019-03-01 2019-03-01
US62/812,878 2019-03-01
US202062962722P 2020-01-17 2020-01-17
US62/962,722 2020-01-17
PCT/US2020/020529 WO2020180741A1 (en) 2019-03-01 2020-02-28 Systems, compositions, and methods for target entity detection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022241629A Division AU2022241629B2 (en) 2019-03-01 2022-10-03 Systems, compositions, and methods for target entity detection

Publications (2)

Publication Number Publication Date
AU2020233286A1 AU2020233286A1 (en) 2021-10-14
AU2020233286B2 true AU2020233286B2 (en) 2022-10-20

Family

ID=72338354

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020233286A Active AU2020233286B2 (en) 2019-03-01 2020-02-28 Systems, compositions, and methods for target entity detection
AU2022241629A Active AU2022241629B2 (en) 2019-03-01 2022-10-03 Systems, compositions, and methods for target entity detection

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022241629A Active AU2022241629B2 (en) 2019-03-01 2022-10-03 Systems, compositions, and methods for target entity detection

Country Status (9)

Country Link
US (3) US20220155304A1 (enExample)
EP (2) EP3998349A3 (enExample)
JP (1) JP7344973B2 (enExample)
KR (1) KR102599718B1 (enExample)
CN (1) CN113748217B (enExample)
AU (2) AU2020233286B2 (enExample)
CA (1) CA3129868A1 (enExample)
SG (1) SG11202109423TA (enExample)
WO (1) WO2020180741A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220155304A1 (en) 2019-03-01 2022-05-19 Mercy Bioanalytics, Inc. Systems, compositions, and methods for target entity detection
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
CA3227133A1 (en) * 2021-07-21 2023-01-26 Mercy Bioanalytics, Inc. Compositions and methods for cancer detection
WO2023004080A2 (en) * 2021-07-21 2023-01-26 Mercy Bioanalytics, Inc. Compositions and methods for detection of pancreatic cancer
WO2023004082A1 (en) * 2021-07-21 2023-01-26 Mercy Bioanalytics, Inc. Compositions and methods for detection of prostate cancer
JP2024529918A (ja) * 2021-07-21 2024-08-14 マーシー バイオアナリティクス， インコーポレイテッド 結腸直腸がんの検出のための組成物および方法
CA3227119A1 (en) * 2021-07-21 2023-01-26 Mercy Bioanalytics, Inc. Compositions and methods for detection of breast cancer
WO2023004079A2 (en) * 2021-07-21 2023-01-26 Mercy Bioanalytics, Inc. Compositions and methods for detection of liver cancer
US20250043357A1 (en) * 2021-07-21 2025-02-06 Mercy Bioanalytics, Inc. Compositions and methods for detection of esophageal cancer
WO2023004083A2 (en) * 2021-07-21 2023-01-26 Mercy Bioanalytics, Inc. Compositions and methods for detection of bile duct cancer
WO2023014863A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
CA3230934A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2023034571A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
EP4623094A1 (en) * 2022-11-23 2025-10-01 Range Biotechnologies, Inc. Compositions and methods for detection of protein analytes
WO2025252658A1 (en) 2024-06-03 2025-12-11 Olink Proteomics Ab New product and method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118987A1 (en) * 1992-11-06 2003-06-26 Charles R. Cantor Positional sequencing by hybridization
US20070275375A1 (en) * 2003-06-17 2007-11-29 Keygene N.V. Means and Method for the Detection of Target Nucleotide Sequences Using Ligation Assays With Improved Oligonucleotide Probe Pairs
WO2016093838A1 (en) * 2014-12-11 2016-06-16 New England Biolabs, Inc. Enrichment of target sequences
US20170253916A1 (en) * 2016-03-04 2017-09-07 University Of Notre Dame Du Lac Exosomal biomarkers diagnostic of tuberculosis

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2118759C (en) 1993-04-21 2004-06-22 William Jeffrey Allard Diagnosis and monitoring of lung cancer patients by measurement of nca 50/90 in blood
US20020025519A1 (en) * 1999-06-17 2002-02-28 David J. Wright Methods and oligonucleotides for detecting nucleic acid sequence variations
US7306904B2 (en) 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing
AU2002353713A1 (en) 2001-11-23 2003-06-10 Simon Fredriksson Method and kit for proximity probing with multivalent proximity probes
JP5117719B2 (ja) 2003-04-18 2013-01-16 ベクトン・ディキンソン・アンド・カンパニー 免疫増幅
WO2005123963A2 (en) 2004-06-14 2005-12-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in analyte detection using proximity probes
GB0605584D0 (en) 2006-03-20 2006-04-26 Olink Ab Method for analyte detection using proximity probes
US8758991B2 (en) 2006-04-26 2014-06-24 University Of Louisville Research Foundation, Inc. Isolation of membrane vesicles from biological fluids and methods of using same
JP5580205B2 (ja) 2007-11-19 2014-08-27 セレラ コーポレーション 肺癌マーカーとその使用
US8481698B2 (en) 2009-03-19 2013-07-09 The President And Fellows Of Harvard College Parallel proximity ligation event analysis
GB201004292D0 (en) 2010-03-15 2010-04-28 Olink Ab Assay for localised detection of analytes
US10669569B2 (en) 2010-10-15 2020-06-02 Navinci Diagnostics Ab Dynamic range methods
EP2638057B1 (en) 2010-11-10 2019-03-06 Exosome Diagnostics, Inc. Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
GB201101621D0 (en) 2011-01-31 2011-03-16 Olink Ab Method and product
ES2744589T3 (es) 2011-05-11 2020-02-25 Exosome Diagnostics Inc Extracción de ácido nucleico de materiales biológicos heterogéneos
CA2836577C (en) * 2011-05-17 2019-06-25 Dxterity Diagnostics Incorporated Methods and compositions for detecting target nucleic acids
GB201108678D0 (en) 2011-05-24 2011-07-06 Olink Ab Multiplexed proximity ligation assay
EP2776587A4 (en) 2011-11-10 2015-07-15 Exosome Diagnostics Inc LIQUOR ASSAY
US9029086B2 (en) 2012-01-26 2015-05-12 Masood Kamali Moghaddam Detection of single and multimodal analytes
WO2014015149A2 (en) 2012-07-18 2014-01-23 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
CA2887058C (en) 2012-10-03 2022-02-22 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
CN104955963A (zh) 2012-11-14 2015-09-30 欧凌科公司 Rca报告探针及其用于检测核酸分子的用途
US10174366B2 (en) 2012-11-14 2019-01-08 Olink Bioscience Ab Localised RCA-based amplification method
US9086412B2 (en) 2012-12-31 2015-07-21 University Of Louisville Research Foundation, Inc. Extracellular vesicle-associated protein markers of cancer
MX392552B (es) 2013-01-03 2025-03-11 Exosome Diagnostics Inc Métodos para aislar microvesículas.
CN106029900B (zh) 2013-08-06 2020-02-28 外来体诊断公司 尿生物标志物群、基因表达特征及其使用方法
CN105980615A (zh) * 2013-08-28 2016-09-28 卡里斯生命科学瑞士控股有限公司 寡核苷酸探针及其用途
WO2015047186A1 (en) 2013-09-30 2015-04-02 Di Wu Methods to profile molecular complexes by using proximity bar-coding
GB201401885D0 (en) 2014-02-04 2014-03-19 Olink Ab Proximity assay with detection based on hybridisation chain reaction (HCR)
EP3110977B1 (en) 2014-02-28 2018-05-16 Exosome Sciences Inc. Brain specific exosome based diagnostics and extracorporeal therapies
KR102497054B1 (ko) * 2014-05-15 2023-02-06 메소 스케일 테크놀러지즈, 엘엘시 개선된 분석 방법
CN113046413A (zh) * 2014-06-06 2021-06-29 康奈尔大学 从血液特异性靶向捕获人类基因组和转录组区域的方法
WO2015193427A1 (en) 2014-06-19 2015-12-23 Olink Ab Determination and analysis of biomarkers in clinical samples
US11175286B2 (en) * 2015-01-09 2021-11-16 Spot Biosystems Ltd. Immunolipoplex nanoparticle biochip containing molecular probes for capture and characterization of extracellular vesicles
AU2016229076B2 (en) * 2015-03-09 2022-01-20 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP4343311A3 (en) * 2015-09-22 2024-05-22 Trustees of Boston University Multiplexed phenotyping of nanovesicles
GB201518655D0 (en) 2015-10-21 2015-12-02 Olink Ab Method for generating proximity probes
SG11201810907UA (en) * 2016-06-06 2019-01-30 Redvault Biosciences Lp Target reporter constructs and uses thereof
EP3548635B1 (en) * 2016-11-30 2021-04-28 Exosome Diagnostics, Inc. Methods to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients
WO2018119455A1 (en) 2016-12-23 2018-06-28 Exosome Diagnostics, Inc. Biofluid analysis and quantitation systems and methods
US11899024B2 (en) 2017-07-12 2024-02-13 Exosome Diagnostics, Inc. Treatment and diagnosis of parkinson's disease using isolated and enriched populations of biofluid-derived extracellular vesicles
EP3655531B1 (en) 2017-07-18 2024-09-04 Exosome Diagnostics, Inc. Sequencing of nucleic acids associated with exosomal isolation from patients with glioblastoma multiforme
EP3660142A4 (en) 2017-07-26 2021-05-05 Rosetta Exosome METHOD OF ISOLATION OF EXTRACELLULAR VESICLES USING CATIONS
WO2019022542A2 (ko) 2017-07-26 2019-01-31 ㈜로제타엑소좀 양이온을 이용한 세포밖 소포체의 분리 방법
WO2019066501A1 (ko) 2017-09-27 2019-04-04 ㈜로제타엑소좀 크기 배제 크로마토그래피를 이용한 세포밖 소포체의 분석 방법 및 이의 용도
WO2019103548A2 (ko) 2017-11-24 2019-05-31 ㈜로제타엑소좀 반건식 크기 배제 크로마토그래피를 이용한 세포밖 소포체의 분리 방법
US20200362334A1 (en) * 2017-12-07 2020-11-19 The Broad Institute, Inc. High-throughput methods for identifying gene interactions and networks
WO2019222708A2 (en) * 2018-05-17 2019-11-21 Meso Scale Technologies, Llc. Methods for isolating surface marker displaying agents
CN112739832B (zh) 2018-06-06 2024-06-04 外来体诊断公司 用于开发尿液生物标志物和用于检测膀胱癌的方法
WO2019238944A1 (en) 2018-06-15 2019-12-19 Olink Proteomics Ab Biomarker panel for ovarian cancer
US20210382043A1 (en) * 2018-10-23 2021-12-09 Meso Scale Technologies, Llc. Methods for isolating surface marker displaying agents
US12258587B2 (en) 2018-11-20 2025-03-25 Exosome Diagnostics, Inc. Compositions and methods for internal controls of microvesicle isolations
US20220155304A1 (en) 2019-03-01 2022-05-19 Mercy Bioanalytics, Inc. Systems, compositions, and methods for target entity detection
JP2023510911A (ja) * 2020-01-17 2023-03-15 マーシー バイオアナリティクス， インコーポレイテッド 卵巣癌を検出するための組成物及び方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118987A1 (en) * 1992-11-06 2003-06-26 Charles R. Cantor Positional sequencing by hybridization
US20070275375A1 (en) * 2003-06-17 2007-11-29 Keygene N.V. Means and Method for the Detection of Target Nucleotide Sequences Using Ligation Assays With Improved Oligonucleotide Probe Pairs
WO2016093838A1 (en) * 2014-12-11 2016-06-16 New England Biolabs, Inc. Enrichment of target sequences
US20170253916A1 (en) * 2016-03-04 2017-09-07 University Of Notre Dame Du Lac Exosomal biomarkers diagnostic of tuberculosis

Also Published As

Publication number Publication date
JP7344973B2 (ja) 2023-09-14
CA3129868A1 (en) 2020-09-10
WO2020180741A1 (en) 2020-09-10
KR102599718B1 (ko) 2023-11-09
AU2022241629B2 (en) 2025-05-29
US20220155304A1 (en) 2022-05-19
EP3931351A4 (en) 2022-05-11
US20210214806A1 (en) 2021-07-15
EP3931351A1 (en) 2022-01-05
JP2022521781A (ja) 2022-04-12
SG11202109423TA (en) 2021-09-29
CN113748217A (zh) 2021-12-03
US11085089B2 (en) 2021-08-10
EP3998349A2 (en) 2022-05-18
CN113748217B (zh) 2023-08-25
AU2020233286A1 (en) 2021-10-14
EP3998349A3 (en) 2022-08-24
US20200299780A1 (en) 2020-09-24
KR20210141952A (ko) 2021-11-23
AU2022241629A1 (en) 2022-10-27
EP3931351B1 (en) 2024-09-11

Similar Documents

Publication Publication Date Title
AU2022241629B2 (en) Systems, compositions, and methods for target entity detection
US20230243834A1 (en) Compositions and methods for detection of ovarian cancer
WO2023004079A2 (en) Compositions and methods for detection of liver cancer
US20240369558A1 (en) Compositions and methods for detection of breast cancer
US20240377401A1 (en) Compositions and methods for detection of prostate cancer
US20240369560A1 (en) Compositions and methods for detection of pancreatic cancer
HK40076883A (en) Compositions and methods for target protein detection on exosomes using proximal ligation
WO2023004077A2 (en) Compositions and methods for detection of colorectal cancer
HK40066670B (en) Method for target entity detection using ligase
HK40066670A (en) Method for target entity detection using ligase
US20250327129A1 (en) Compositions and methods for detection of ovarian cancer

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: MERCY BIOANALYTICS, INC.

Free format text: FORMER NAME(S): MERCY BIOANALYTICS, INC.

FGA Letters patent sealed or granted (standard patent)